CAS: 1258292-64-6 - 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
GDC-046 REF: 7W-GW5412CAS: 1258292-64-6 | - - - | 241.00 €~595.00 € | Fri 17 Jan 25 | |
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide REF: TM-T22338CAS: 1258292-64-6 | 98.77% | 60.00 €~852.00 € | Fri 17 Jan 25 | |
GDC046 REF: 3D-IAC29264CAS: 1258292-64-6 | Min. 95% | To inquire | Fri 21 Feb 25 | |
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide REF: IN-DA00A18MCAS: 1258292-64-6 | 99% | - - - | Discontinued product |
Ref: 7W-GW5412
1mg | 241.00 € | ||
5mg | 383.00 € | ||
10mg | 595.00 € |
Estimated delivery in United States, on Friday 17 Jan 2025
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:1258292-64-6
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.
Formula:
C16H13Cl2N3O2
Purity:
98.77%
Color and Shape:
Solid
Molecular weight:
350.2
Ref: TM-T22338
1mg | 60.00 € | ||
5mg | 118.00 € | ||
10mg | 184.00 € | ||
25mg | 423.00 € | ||
50mg | 611.00 € | ||
100mg | 852.00 € |
Estimated delivery in United States, on Friday 17 Jan 2025
GDC046
CAS:1258292-64-6
GDC046 is a triazole compound with inhibitory properties that acts as a tyrosine kinase inhibitor. …
Formula:
C16H13Cl2N3O2
Purity:
Min. 95%
Molecular weight:
350.2 g/mol
Ref: 3D-IAC29264
10mg | 758.00 € | ||
25mg | 1,338.00 € | ||
50mg | 1,861.00 € |
Estimated delivery in United States, on Friday 21 Feb 2025
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:1258292-64-6
Formula:
C16H13Cl2N3O2
Purity:
99%
Color and Shape:
Solid
Molecular weight:
350.1993
Ref: IN-DA00A18M
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information |